Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital lowered their price objective on Evogene from $30.00 to $12.00 and set a buy rating for the company in a research report on Friday, August 23rd.

Evogene Trading Up 3.6 %

Evogene stock opened at $2.59 on Wednesday. The stock has a 50 day moving average of $3.27 and a two-hundred day moving average of $5.48. The stock has a market capitalization of $106.75 million, a price-to-earnings ratio of -5.63 and a beta of 1.40. Evogene has a twelve month low of $2.29 and a twelve month high of $10.40.

Evogene (NASDAQ:EVGN) last released its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The firm had revenue of $0.91 million during the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.